Retatrutide Phase 3 data: what sits below the headline figure
The 28.3% figure for retatrutide comes from one trial population. Other TRIUMPH topline results show a lower average in type 2 diabetes, a sensory signal, and an open cardiovascular question.
The figure most often quoted for retatrutide is a 28.3% average weight reduction. The numbers further down the same company announcements are less tidy. This article reads five findings from the Phase 3 TRIUMPH program that rarely reach the headline, with attention to which population each number describes and how much of it has been peer reviewed.
The headline number depends on the population
The 28.3% result came from TRIUMPH-1, which excluded people with diabetes. In TRIUMPH-2, which enrolled 1,152 adults with type 2 diabetes and ran for 80 weeks, the top arm averaged a 20.8% reduction. It is the same molecule in a different population, and the averages differ accordingly.
Safety signals in TRIUMPH-2 and TRIUMPH-3
Dysesthesia, an altered or unpleasant skin sensation, was reported by 4.5% to 7.3% of retatrutide participants in TRIUMPH-2, compared with 0.7% on placebo. In TRIUMPH-3 the figures were 6.4% and 1.3%. Lilly described the events as generally mild to moderate, with most resolving during the trial. The mechanism behind the signal has not been explained.
Discontinuation due to adverse events was also higher in the top arm of TRIUMPH-3, at 13.5% compared with 4.8% on placebo.
The cardiovascular question is still open
TRIUMPH-3 enrolled 1,949 adults with established cardiovascular disease. The hazard ratio for major cardiovascular events was 0.82, with a confidence interval of 0.55 to 1.22. Because that interval crosses 1, the result shows neither benefit nor harm.
Risk markers did move in the same trial: triglycerides fell by 37% and hsCRP by 51%. A change in a marker is not the same as a change in outcomes, and the outcome data remain inconclusive.
Topline data, not peer-reviewed results
Every Phase 3 number above is topline data taken from company announcements: the Eli Lilly releases of May 21, 2026 (TRIUMPH-1, NCT05929066) and July 23, 2026 (TRIUMPH-2, NCT05929079; TRIUMPH-3, NCT05882045). The full datasets come later, and details may change when they are published.
What is known is that five Phase 3 trials reported large average weight reductions. What is claimed online, that retatrutide is proven better and safer than everything before it, has not been shown by any trial. Retatrutide is investigational and not FDA-approved, and Lilly has said it plans to file in the first quarter of 2027.